Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Turn TherapeuticsTTRX +10.89%11 PB Ratio is 40.24 as of Jul. 30, 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. Among 1,228 Biotechnology companies, Turn Therapeutics ranks worse than 96.74% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Turn Therapeutics PB Ratio Related Terms
Turn Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Turn Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Turn Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turn Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turn Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Turn Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Turn Therapeutics (TTRX) has a PB Ratio of 40.24 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Turn Therapeutics and its competitors. According to the industry distribution chart, Turn Therapeutics ranks #1188 out of 1228 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Turn Therapeutics' PB Ratio too high?
Turn Therapeutics' current PB Ratio is 40.24. The Biotechnology industry median PB Ratio is 2.69. Turn Therapeutics' value of 40.24 is 1395.9% above this industry median. Based on the distribution chart, Turn Therapeutics ranks #1188 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' PB Ratio compare to IRD and VRXA?
According to the Biotechnology industry distribution chart, Turn Therapeutics ranks #1188 out of 1228 companies for PB Ratio. This places Turn Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.69. Turn Therapeutics' value of 40.24 is 1395.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.69, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turn Therapeutics's current PB Ratio of 40.24 is 1395.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Turn Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turn Therapeutics's current PB Ratio is 40.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current PB Ratio of 40.24. The current PB Ratio is 40.24 and 1395.9% above the Biotechnology industry median of 2.69. Turn Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current PB Ratio is 40.24 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score
Get the complete analysis for TTRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TTRX has been successfully added to your 
